BioLineRx Ltd.
- BLRX
- NASDAQ
- Biotechnology
- Oncology Biotech
- Peptide Therapeutics
$1.98
Today −1.49%Quote Oct 19, 2026, 08:00 PM UTC
−20.39%over the last month
Max drawdown −23.8%From 1-month high −23.8%3 months −32.2%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About BioLineRx
BioLineRx Ltd., an Israeli biopharmaceutical firm established in 2003 and based in Hevel Modi'in, focuses its clinical-stage development efforts primarily on oncology. Their leading investigational product, Motixafortide, a peptide, has successfully concluded pivotal Phase 3 clinical trials for mobilizing stem cells in autologous transplants, and Phase 2a trials targeting pancreatic cancer.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
22
Market value
$5.17B
Quote Oct 19
Floor
$1.95
1.5% below price
Resistance
$2.10
6.1% above price
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about BLRXPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free